Detergents profoundly affect inhibitor potencies against both cyclo-oxygenase isoforms

Biochemical Journal

Volumn 377, Issue 3, 2004, Pages 675-684

  Ouellet, Marc ^a   Falgueyret, Jean Pierre ^a   Percival, M David ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

Cyclo oxygenase; Detergent; Genapol X 100; Nonsteroidal anti inflammatory drug (NSAID); Prostaglandin H synthase

Indexed keywords

BIOASSAY; BIOCHEMISTRY; CALORIMETRY; DETERGENTS; MICELLES; TITRATION;

REDUCING AGENTS;

ENZYME INHIBITION;

5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; ARACHIDONIC ACID; CARBON 14; CARPROFEN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DETERGENT; DICLOFENAC; FLOSULIDE; FLUFENAMIC ACID; GENAPOL X 100; IBUPROFEN; INDOMETACIN; ISOENZYME; ISOXICAM; KETOPROFEN; MECLOFENAMIC ACID; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; N,N,N',N' TETRAMETHYL 1,4 PHENYLENEDIAMINE; NAPROXEN; NIFLUMIC ACID; NIMESULIDE; OCTYL GLUCOSIDE; PHOSPHATIDYLCHOLINE; PIROXICAM; POLYSORBATE 20; TRITON X 100; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOMEPIRAC;

ARTICLE; COLORIMETRY; DRUG ANTAGONISM; DRUG BINDING; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; DRUG SENSITIVITY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC 50; MICELLE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; TIME; TITRIMETRY;

EID: 1242292286     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/bj20030969     Document Type: Article

References (48)

1. Smith, W. L. and Song, I. (2002) The enzymology of prostaglandin endoperoxide H synthases-1 and -2. Prostaglandins Other Lipid. Mediat. 68-69, 115-128
2. van der Donk, W. A., Tsai, A. L. and Kulmacz, R. J. (2002) The cyclooxygenase reaction mechanism. Biochemistry 41, 15451-15458
3. Kurumbail, R. G., Kiefer, J. R. and Marnett, L. J. (2001) Cyclooxygenase enzymes: catalysis and inhibition. Curr. Opin. Struct. Biol. 11, 752-760
4. Smith, W. L., DeWitt, D. L. and Garavito, R. M. (2000) Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69, 145-182
5. Smith, W. L. and Langenbach, R. (2001) Why there are two cyclooxygenase isozymes. J. Clin. Invest. 107, 1491-1495
6. Buttgereit, F., Burmester, G. R. and Simon, L. S. (2001) Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors. Am. J. Med. 110, 13S-9S
7. Cannon, G. W. and Breedveld, F. C. (2001 ) Efficacy of cyclooxygenase-2-specific inhibitors. Am. J. Med. 110, 6S-12S
8. van Ryn, J. and Pairet, M. (1999) Clinical experience with cyclooxygenase-2 inhibitors. Inflamm. Res. 48, 247-254
9. Hanel, A. M. and Lands, W. E. (1982) Modification of anti-inflammatory drug effectiveness by ambient lipid peroxides. Biochem. Pharmacol. 31, 3307-3311
10. Ouellet, M. and Percival, M. D. (2001) Mechanism of acetaminophen inhibition of cyclooxygenase isoforms. Arch. Biochem. Biophys. 387, 273-280
11. Boutaud, O., Aronoff, D. M., Richardson, J. H., Marnett, L. J. and Oates, J. A. (2002) Determinants of the cellular specificity of acetaminophen as an inhibitor of prostaglandin H(2) synthases. Proc. Natl Acad. Sci. U.S.A. 99, 7130-7135
12. Aronoff, D. M., Boutaud, O., Marnett, L. J. and Oates, J. A. (2003) Inhibition of prostaglandin H2 synthases by salicylate is dependent on the oxidative state of the enzymes. J. Pharmacol. Exp. Ther. 304, 589-595
13. Egan, R. W., Humes, J. L. and Kuehl, Jr, F. A. (1978) Differential effects of prostaglandin synthetase stimulators on inhibition of cyclooxygenase. Biochemistry 17, 2230-2234
14. Rome, L. H. and Lands, W. E. (1975) Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs. Proc. Natl. Acad. Sci. U.S.A. 72, 4863-4865
15. Mevkh, A. T., Sud'ina, G. F., Golub, N. B. and Varfolomeev, S. D. (1985) Purification of prostaglandin H synthetase and a fluorometric assay for its activity. Anal. Biochem. 150, 91-96
16. Forghani, F., Ouellet, M., Keen, S., Percival, M. D. and Tagari, P. (1998) Analysis of prostaglandin G/H synthase-2 inhibition using peroxidase-induced luminol luminescence. Anal. Biochem. 264, 216-221
17. Kulmacz, R. J. (1987) Prostaglandin G2 levels during reaction of prostaglandin H synthase with arachidonic acid. Prostaglandins 34, 225-240
18. Johnson, A. R., Marletta, M. A. and Dyer, R. D. (2001) Slow-binding inhibition of human prostaglandin endoperoxide synthase-2 with darbufelone, an isoform-selective antiinflammatory di-tert-butyl phenol. Biochemistry 40, 7736-7745
19. Copeland, R. A., Williams, J. M., Giannaras, J., Nurnberg, S., Covington, M., Pinto, D., Pick, S. and Trzaskos, J. M. (1994) Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc. Natl. Acad. Sci. U.S.A. 91, 11202-11206
20. Cromlish, W. A., Payette, P., Culp, S. A., Ouellet, M., Percival, M. D. and Kennedy, B. P. (1994) High-level expression of active human cyclooxygenase-2 in insect cells. Arch. Biochem. Biophys. 314, 193-199
21. Percival, M. D., Ouellet, M., Vincent, C. J., Yergey, J. A., Kennedy, B. P. and O'Neill, G. P. (1994) Purification and characterization of recombinant human cyclooxygenase-2. Arch. Biochem. Biophys. 315, 111-118
22. Ouellet, M. and Percival, M. D. (1995) Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem. J. 306, 247-251
23. Timofeevski, S. L., Prusakiewicz, J. J., Rouzer, C. A. and Marnett, L. J. (2002) Isoform-selective interaction of cyclooxygenase-2 with indomethacin amides studied by real-time fluorescence, inhibition kinetics, and site-directed mutagenesis. Biochemistry 41, 9654-9662
24. Menguy, T., Chenevois, S., Guillain, F., le Maire, M., Falson, P. and Champeil, P. (1998) Ligand binding to macromolecules or micelles: use of centrifugal ultrafiltration to measure low-affinity binding. Anal. Biochem. 264, 141-148
25. Kulmacz, R. J. and Lands, W. E. (1985) Stoichiometry and kinetics of the interaction of prostaglandin H synthase with anti-inflammatory agents. J. Biol. Chem. 260, 12572-12578
26. Gierse, J. K., Koboldt, C. M., Walker, M. C., Seibert, K. and Isakson, P. C. (1999) Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem. J, 339, 607-614
27. Walker, M. C., Kurumbail, R. G., Kiefer, J. R., Moreland, K. T., Koboldt, C. M., Isakson, P. C., Seibert, K. and Gierse, J. K. (2001) A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors. Biochem. J. 357, 709-718
28. Smith, C. J., Zhang, Y., Koboldt, C. M., Muhammad, J., Zweifel, B. S., Shaffer, A., Talley, J. J., Masferrer, J. L., Seibert, K. and Isakson, P. C. (1998) Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc. Natl. Acad. Sci. U.S.A. 95, 13313-13318
29. Riendeau, D., Percival, M. D., Boyce, S., Brideau, C., Charleson, S., Cromlish, W., Ethier, D., Evans, J., Falgueyret, J. P., Ford-Hutchinson, A. W. et al. (1997) Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br. J. Pharmacol. 121, 105-117
30. Chan, C. C., Boyce, S., Brideau, C., Charleson, S., Cromlish, W., Ethier, D., Evans, J., Ford-Hutchinson, A. W., Forrest, M. J., Gauthier, J. Y. et al. (1999) Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2- (5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J. Pharmacol. Exp. Ther. 290, 551-560
31. Riendeau, D., Percival, M. D., Brideau, C., Charleson, S., Dube, D., Ethier, D., Falgueyret, J. P., Friesen, R. W., Gordon, R., Greig, G. et al. (2001) Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J. Pharmacol. Exp. Ther. 296, 558-566
32. Selinsky, B. S., Gupta, K., Sharkey, C. T. and Loll, P. J. (2001) Structural analysis of NSAID binding by prostaglandin H2 synthase: time-dependent and time-independent inhibitors elicit identical enzyme conformations. Biochemistry 40, 5172-5180
33. Swinney, D. C., Mak, A. Y., Barnett, J. and Ramesha, C. S. (1997) Differential allosteric regulation of prostaglandin H synthase 1 and 2 by arachidonic acid. J. Biol. Chem. 272, 12393-12398
34. Bayly, C. I., Black, W. C., Leger, S., Ouimet, N., Ouellet, M. and Percival, M. D. (1999) Structure-based design of COX-2 selectivity into flurbiprofen. Bioorg. Med. Chem. Lett. 9, 307-312
35. Cann, J. R. and Hinman, N. D. (1976) Hummel-Dreyer gel chromatographic procedure as applied to ligand-mediated association. Biochemistry 15, 4614-4622
36. Miki, T. and Orii, Y. (1985) The reaction of horseradish peroxidase with hydroperoxides derived from Triton X-100. Anal. Biochem. 146, 28-34
37. Benoit, E., Delatour, P., Olivier, L. and Caldwell, J. (1995) (-)-R-fenoprofen: formation of fenoprofenyl-coenzyme A by rat liver microsomes. Biochem. Pharmacol. 49, 1717-1720
38. Spinedi, A., Pacini, L., Limatola, C., Luly, P. and Farias, R. N. (1991) A study of human erythrocyte acetylcholinesterase inhibition by chlorpromazine. Biochem. J. 278, 461-463
39. Wu, Y., Zhou, C. and Roberts, M. F. (1997) Stereocontrolled syntheses of water-soluble inhibitors of phosphatidylinositol-specific phospholipase C: inhibition enhanced by an interface. Biochemistry 36, 356-363
40. Coughlan, S. J., Davenport, J. W. and Hind, G. (1991) Reactive blue 2 is a potent inhibitor of a thylakoid protein kinase. Eur. J. Biochem. 197, 467-471
41. Lanzo, C. A., Sutin, J., Rowlinson, S., Talley, J. and Marnett, L. J. (2000) Fluorescence quenching analysis of the association and dissociation of a diarylheterocycle to cyclooxygenase-1 and cyclooxygenase-2: dynamic basis of cyclooxygenase-2 selectivity. Biochemistry 39, 6228-6234
42. Callan, O. H., So, O. Y. and Swinney, D. C. (1996) The kinetic factors that determine the affinity and selectivity for slow binding inhibition of human prostaglandin H synthase 1 and 2 by indomethacin and flurbiprofen. J. Biol. Chem. 271, 3548-3554
43. Morrison, J. F. and Walsh C. T. (1988) The behavior and significance of slow-binding enzyme inhibitors. Adv. Enzymol. Relat. Areas Mol. Biol. 61, 201-301
44. Morgenstern, R. (1998) A simple alternate substrate test can help determine the aqueous or bilayer location of binding sites for hydrophobic ligands/substrates on membrane proteins. Chem. Res. Toxicol. 11, 703-707
45. Luong, C., Miller, A., Barnett, J., Chow, J., Ramesha, C. and Browner, M. F. (1996) Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat. Struct. Biol. 3, 927-933
46. So, O. Y., Scarafia, L. E., Mak, A. Y., Callan, O. H. and Swinney, D. C. (1998) Studies with prostaglandin H synthase 2 Y355F unmask mechanisms of time-dependent inhibition and allosteric activation. J. Biol. Chem. 273, 5801-6807
47. Picot, D., Loll, P. J. and Garavito, R. M. (1994) The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature (London) 367, 243-249
48. Smith, T., Leipprandt, J. and DeWitt, D. (2000) Purification and characterization of the human recombinant histidine-tagged prostaglandin endoperoxide H synthases-1 and -2. Arch. Biochem. Biophys. 375, 195-200